Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.

Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero Y Calle M, Deleu L, Sommer C, Thomas N, Rommelaere J, Schlehofer JR.

Neuro Oncol. 2010 Aug;12(8):804-14. doi: 10.1093/neuonc/noq023.

2.

Regression of glioma in rat models by intranasal application of parvovirus h-1.

Kiprianova I, Thomas N, Ayache A, Fischer M, Leuchs B, Klein M, Rommelaere J, Schlehofer JR.

Clin Cancer Res. 2011 Aug 15;17(16):5333-42. doi: 10.1158/1078-0432.CCR-10-3124.

3.

Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.

Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR.

Bioeng Bugs. 2010 Nov-Dec;1(6):429-33. doi: 10.4161/bbug.1.6.12943.

4.

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.

J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57.

PMID:
17077357
5.

Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.

Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, Rommelaere J.

Oncol Rep. 2007 Jun;17(6):1493-9.

PMID:
17487410
6.

Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.

Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR.

J Biomed Biotechnol. 2010;2010:350748. doi: 10.1155/2010/350748.

7.

Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.

Grekova SP, Aprahamian M, Daeffler L, Leuchs B, Angelova A, Giese T, Galabov A, Heller A, Giese NA, Rommelaere J, Raykov Z.

Cancer Biol Ther. 2011 Nov 15;12(10):888-95. doi: 10.4161/cbt.12.10.17678.

8.

Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.

Wei J, Wahl J, Nakamura T, Stiller D, Mertens T, Debatin KM, Beltinger C.

Gene Ther. 2007 Nov;14(22):1573-86.

PMID:
17898797
9.

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.

Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B, Hajda J.

BMC Cancer. 2012 Mar 21;12:99. doi: 10.1186/1471-2407-12-99.

10.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

11.

Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells.

Di Piazza M, Mader C, Geletneky K, Herrero Y Calle M, Weber E, Schlehofer J, Deleu L, Rommelaere J.

J Virol. 2007 Apr;81(8):4186-98.

12.

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.

Grekova S, Aprahamian M, Giese N, Schmitt S, Giese T, Falk CS, Daeffler L, Cziepluch C, Rommelaere J, Raykov Z.

Cancer Biol Ther. 2010 Dec 15;10(12):1280-9.

PMID:
21124075
13.

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.

Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342.

14.

Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2010 Jan 15;70(2):598-608. doi: 10.1158/0008-5472.CAN-09-1510.

15.

Reovirus as an oncolytic agent against experimental human malignant gliomas.

Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA.

J Natl Cancer Inst. 2001 Jun 20;93(12):903-12.

PMID:
11416111
16.

Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.

Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt AJ, Szalay AA.

Clin Cancer Res. 2012 May 1;18(9):2579-90. doi: 10.1158/1078-0432.CCR-11-2394.

17.

Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.

Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS.

Stem Cells. 2008 Mar;26(3):831-41. doi: 10.1634/stemcells.2007-0758.

18.

Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.

Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M, Dinsart C, Rommelaere J, Galle PR.

BMC Cancer. 2011 Oct 26;11:464. doi: 10.1186/1471-2407-11-464.

19.

Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.

Liu Z, Zhao X, Mao H, Baxter PA, Huang Y, Yu L, Wadhwa L, Su JM, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Hurwitz RL, Lau CC, Chintagumpala M, Blaney SM, Li XN.

Neuro Oncol. 2013 Sep;15(9):1173-85. doi: 10.1093/neuonc/not065.

20.

Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.

Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E.

Clin Cancer Res. 2007 Dec 1;13(23):7155-65.

Items per page

Supplemental Content

Support Center